Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Recurrent or metastatic melanoma as defined by stage IV disease (distant metastases), or any recurrent melanoma manifested by lymph node metastases or soft tissue nodules~* ECOG Performance status of 0-2~* Satisfactory medical condition for treatment in a phase I-II trial of anticancer therapy~* Age \> 16 years~* Venous access for leukopheresis procedure to obtain peripheral blood lymphocytes to generate dendritic cells.~* Serum pregnancy test must be negative for women of childbearing potential.~Exclusion Criteria:~* Active central nervous system metastases~* Known autoimmune disease or disease process that involves the use of immunosuppressive therapy.~* Underlying cardiac disease associated with New York Heart Association class III or IV function, or unstable angina related to atherosclerotic cardiovascular disease.~* Ongoing transfusion requirements, no significant hepatic or renal dysfunction, creatinine \< 2.0 mg/dl, bilirubin \< 2.0 mg/dl, albumin \> 3.0 mg/dl, hematocrit \> 25, platelets \> 100,000.~* Active infection or other active medical condition that could be eminently life threatening, including no active blood clotting or bleeding diathesis.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).